Survival Outcomes of Head and Neck Neuroendocrine Carcinoma: A Systematic Review.
Morena Aïta, Ilario Galofaro, Antonino Maniaci et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined survival outcomes in patients with head and neck neuroendocrine carcinoma (HNNEC), focusing on tumor characteristics and treatment strategies. The review found that surgical cohorts had a 5-year overall survival (OS) ranging from 33.0% to 73.9%, while multimodal treatment achieved 57.2% to 61.0% OS. The study highlights significant variability in treatment approaches and outcomes based on tumor location and histology.
Key findings
- 5-year overall survival for surgical cohorts ranged from 33.0% to 73.9%.
- Multimodal treatment achieved overall survival rates of 57.2% to 61.0%.
- Well/moderately-differentiated carcinoids had better outcomes than poorly-differentiated and small-cell variants.
- Laryngeal tumors showed more favorable outcomes compared to sinonasal/salivary tumors.
Why it matters
Understanding the survival outcomes and treatment efficacy for HNNEC is crucial for clinicians to make informed decisions regarding management strategies. The variability in outcomes based on histology and tumor location underscores the need for tailored treatment approaches.